Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 97
- Registration Number
- NCT04367090
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 233
- Registration Number
- NCT04346381
- Locations
- 🇨🇳
Fudan University Zhongshan Hospital, Shanghai, Shanghai, China
Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT04342936
- Locations
- 🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 550
- Registration Number
- NCT04342910
- Locations
- 🇨🇳
Affiliated Hospital, Academy of Military Medical Sciences, Beijing, China
Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2020-04-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04341077
A Food Effect Study of Apatinib Mesylate in Healthy Subjects
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT04341090
- Locations
- 🇨🇳
Beijing Luhe Hospital, Capital Medical University, Beijing, Beijing, China
A Food Effect Study of SHR2554 on Healthy Chinese Male Adult Subjects
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04335266
- Locations
- 🇨🇳
Henan Cancer Hospital, Henan, China
A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT04335006
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 566
- Registration Number
- NCT04333771
- Locations
- 🇨🇳
Liuzhou workers' Hospital, Liuzhou, Guangxi, China
A Study to Compare Pharmacokinetic and Safety Profiles of Different Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04326881
© Copyright 2024. All Rights Reserved by MedPath